Results 171 to 180 of about 10,598 (216)

Application Value of Multi-Gene Testing in the Evaluation of Benign and Malignant Thyroid Nodules. [PDF]

Iran J Biotechnol
Zhang M, Xie L, Xu F, Liu L, Wang Y, Jiang J, Fei W, Jiang Z, Hu X.   +8 more
europepmc   +1 more source

How to manage radioiodine-refractory thyroid cancer in the era of precision medicine. [PDF]

Drugs Context
Karapanou O, Effraimidis G, Michalaki M, Saltiki K.   +3 more
europepmc   +1 more source

Delayed growth of SK-ES-1 Ewing sarcoma tumor xenografts is associated with reduced Trk and IGF1R pathway markers. [PDF]

Oncotarget
Dos Santos BA, Freire NXLH, Fratini L, Dalmolin M, Castro JM, Fernandes MAC, Gregianin L, Brunetto AXT, Brunetto AL, Rivero LFDR, Jaeger MDC, Roesler R, de Farias CB.   +12 more
europepmc   +1 more source

Clinicopathological and sonographic characterization of NTRK-fusion papillary thyroid carcinoma based on preoperative molecular testing: a comparative study with BRAF^V600E PTC. [PDF]

Front Oncol
Zhang Y, Zou D, Wu X, Han M, Gai J, Ding W, Xu S, Liu C, Wu X, Wang Y.   +9 more
europepmc   +1 more source

Latin American Thyroid Society expert panel consensus on anaplastic thyroid cancer. [PDF]

Arch Endocrinol Metab
Califano I, Callegari FM, Cerutti JM, Chaves ALF, Castro G, Ruiz-Tagle JMD, Falco A, Hoff AAO, Kowalski LP, Maia AL, Pereira MD, Sanabria A, Pitoia F.   +12 more
europepmc   +1 more source

Real-World Treatment Patterns and Clinical Outcomes After First-Line Therapy in Patients with KRAS G12C-Mutant Advanced Non-Small-Cell Lung Cancer in the United States. [PDF]

Cancers (Basel)
Sheffield KM, Puri T, Thoele K, Karu H, Mansharamani A, Uprety D.   +5 more
europepmc   +1 more source

Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma. [PDF]

Oncologist
Rohlfing S, Vladimirova D, Berger S, Bochum S, Otmacic G, Weiß M, Sipos B, Biskup S, Klaumünzer M, Martens UM.   +9 more
europepmc   +1 more source

Implementation Benchmark of Tumor-Agnostic Eligibility Signals Across Routine Comprehensive Genomic Profiling Platforms in Japan: A Nationwide C-CAT Analysis. [PDF]

Curr Oncol
Kajiura S, Nakamura N, Hayashi R.
europepmc   +1 more source

Biomarker testing in advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer: expert recommendations. [PDF]

Ther Adv Med Oncol
Reinert T, Alshehri AS, Shafik A, Lin CH, Gomez Abuin G, Gong G, Jung KH, Amat M, Pathmanathan N, Ow SGW, Rivera-Rivera S, Aggarwal S, Luen SJ, Yong Tay TK.   +13 more
europepmc   +1 more source

Panel-negative strategy for suspected fusion-driven papillary thyroid carcinoma. [PDF]

Thyroid Res
Okubo Y, Takada I, Kadoya M, Toda S, Wada S, Masudo K, Miyagi Y, Hayashi H.   +7 more
europepmc   +1 more source